Wounds are personal. They steal independence, dignity, and time. ZegeneX exists to change what happens after a wound forms — for the patient, the family, the clinician, and the system that cares for them.
The numbers behind the global wound-care crisis — measured in lives, limbs and lost futures.
Diabetic foot ulcer patients globally
US patients with chronic, non-healing wounds
US lower-limb amputations every year
Failure rate of current standard of care
5-year mortality after a major lower-limb amputation due to DFU is worse than most cancers. Yet only 6% of US DFU patients ever receive advanced therapy. The other 94% rely on dressings and pressure therapy that don’t address the underlying biology.
From a grandmother in a rural clinic to a soldier in the field — ZegeneX is engineered so that wound healing isn’t a privilege of geography or income.
For the 537 million adults living with diabetes worldwide, a small foot ulcer can become a death sentence. We exist to close those wounds before they become catastrophes.
In trauma medicine, the cold chain is a luxury you can’t carry. A shelf-stable therapeutic that survives a Humvee for 24 months changes battlefield wound care.
In rural clinics across sub-Saharan Africa, South Asia and Latin America, refrigeration is unreliable. Cold-chain-free changes which patients get advanced therapy.
For the spouse changing dressings nightly, an effective topical that lives on the nightstand for months is the difference between hope and helplessness.
Post-op wound complications drive readmissions and bad outcomes. A topical that reliably accelerates closure means better recoveries and lower costs.
Chronic wounds consume tens of billions in annual US spend. A therapy that closes wounds faster cuts amputations, readmissions and length-of-stay together.
Every day saved on the wound bed compounds into something bigger.
Days of pain avoided per patient on average
Infection risk window compressed dramatically
Limb saved for every wound that closes in time
Independence restored — walking, working, living
Our work directly supports several UN Sustainable Development Goals and the WHO essential-medicines vision for accessible advanced care.
Reducing premature mortality from non-communicable disease complications, including diabetes-related amputations.
Eliminating the cold-chain barrier that has historically locked advanced therapies out of low-income markets.
Designed to meet WHO criteria for stability, ease of use, and affordability — engineered for true global health utility from Day 1.
Partner with us to bring shelf-stable, advanced wound care to the patients and providers who need it most.
A preclinical-stage biopharmaceutical company developing first-in-class, shelf-stable wound healing therapeutics — making advanced care accessible everywhere.
